Page 30 - Gates-AnnualReport-2017

COMMERCIALIZATION
Getting great ideas out of the lab and off the shelf is critical to realizing future therapies. In a world of shrinking public funding, we need new solutions like venture philanthropy, forward-thinking business/investor partnerships, and competitive ‘valley of death’ funding to drive innovation and keep brilliant investigators in the game.
—Diane Gates Wallach, Co-Chair, Gates Center Advisory Board
With new solutions in mind, the Gates Grubstake Fund was incorporated as a private 501(c)(3) foundation and a key component of the Gates Center for Regenerative Medicine’s commercialization strategy for projects and teams affiliated with the Gates Center. Overseen by the Gates Center with deep support from CU Innovations, Grubstake Fund investment decisions are made on a competitive basis by a Scientific Investment Advisory Committee (SIAC) comprised of subject matter experts and institutional investors with a focus on biotechnology:
• William Hiatt, M.D., Professor, Division of Cardiology, University of Colorado Anschutz Medical Campus; President, CPC Clinical Research
• Ryan Kirkpatrick, Partner, Colorado Impact Fund
• David L. Lacey M.D., Biopharmaceutical Consultant, former SVP, head of research, Amgen
• Mark Lupa, Ph.D., Principal, High Country Ventures
• Kimberly Muller, J.D., Managing Director, CU Innovations, University of Colorado Anschutz Medical Campus
• Michael Perry, DVM, Ph.D., FACVPT, Chief Executive Officer, Avita Medical Ltd.; Managing Director, Bioscience Managers
Pty Ltd
• Mark Petrash, Ph.D., Professor and Vice Chair, Department of Ophthalmology, Associate Director, Gates Center for
Regenerative Medicine, University of Colorado Anschutz Medical Campus
• Geoff “Duffy” Solich, Executive Vice President, E & P Resources LLC; member, Gates Center Advisory Board
• Ann Sperling, Senior Director, Trammell Crow Company; member, Gates Advisory Board
• Robert Traver, J.D., Patent Attorney, Sheridan Ross
30 Gates Center for Regenerative Medicine